Nab-paclitaxel/Paclitaxel
Nab-paclitaxel/Paclitaxel 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Breast Neoplasms。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
5 项
已进入 III/IV 期
25 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- BioNTech SE
- Kochi University
- UNC Lineberger Comprehensive Cancer Center
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- TCRCure Biopharma Ltd.
- Zhejiang Cancer Hospital
- Chang Gung Memorial Hospital
- Taiho Pharmaceutical Co., Ltd.
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
日本、美国、中国、中国台湾、Israel、Chile、Greece、Hungary、意大利、Poland、西班牙、Turkey (Türkiye)
正在招募患者的 Nab-paclitaxel/Paclitaxel 研究
Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
II 期 / III 期招募中日本NCT05268692Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
I 期 / II 期招募中美国NCT06483555Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)
II 期招募中中国NCT04807140NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
I 期招募中中国NCT05881525Pucotenlimab and Anlotinib in Combination With Chemotherapy
II 期招募中中国NCT07896668Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma
I 期招募中中国台湾NCT06229496AB122 Platform Study
I 期招募中日本NCT04999761A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers
II 期招募中美国Israel日本中国台湾NCT07769502Second-line Immunotherapy for ES-SCLC
不适用招募中中国NCT06853678Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
II 期招募中中国NCT04138719A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
II 期招募中美国ChileGreeceHungaryNCT06731907Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ
II 期招募中中国NCT06808971AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
III 期招募中中国NCT06767527Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
II 期招募中美国NCT06865339Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
III 期招募中美国澳大利亚奥地利比利时NCT07491445Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
III 期招募中美国加拿大NCT06958328Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer
II 期招募中中国NCT07867392Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
II 期招募中中国NCT06446726Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
II 期招募中中国NCT07393425Serplulimab for Locally Advanced Cervical Cancer
II 期招募中中国NCT07340489BBO-11818 in Adult Subjects With KRAS Mutant Cancer
I 期招募中美国澳大利亚NCT06917079Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer
II 期招募中中国NCT07876154ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
III 期招募中美国Argentina澳大利亚比利时NCT07173751Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
II 期招募中美国NCT04926467
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。